Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 5,150 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acquired Immunodeficiency Syndromes Clear all
Completed Phase 2 Interventional

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

NCT00000870
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 30, 2026, 1:27 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects

NCT00743470
View directory record Official record
Conditions
HIV, Tuberculosis
Interventions
lopinavir/ritonavir, rifabutin
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

NCT00119873
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
3
States / cities
San Francisco, California • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 30, 2026, 1:27 PM EDT
Terminated Phase 4 Interventional

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc

NCT00981318
View directory record Official record
Conditions
HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
lopinavir/ritonavir plus maraviroc
Drug
Lead sponsor
Rodwick, Barry M., M.D.
Individual
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Safety Harbor, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 30, 2026, 1:27 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Neural Correlates of Working Memory Training for HIV Patients

NCT02602418
View directory record Official record
Conditions
HIV Infection
Interventions
Adaptive WM CogMed Training, Nonadaptive WM CogMed Training
Other
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of a Telenovela/Soap Opera for HIV Prevention in Latinas

NCT05929482
View directory record Official record
Conditions
HIV Infections
Interventions
Infección de Amor (Infectious Love)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

NCT04371380
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir extended release suspension for injection (long-acting), Rilpivirine extended release suspension for injection (long-acting)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Not applicable Interventional

Managed Problem Solving to Increase Treatment Adherence in Individuals With HIV

NCT00130273
View directory record Official record
Conditions
HIV Infections
Interventions
Managed problem solving, Standard care
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Doxy-Post-exposure Prophylaxis

NCT05853120
View directory record Official record
Conditions
Sexually Transmitted Diseases
Interventions
Doxycycline
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 59 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 30, 2026, 1:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Education and Employment Support for HIV Prevention in Young Adults (ENSPIRE)

NCT06096324
View directory record Official record
Conditions
Economic Hardship, Condomless Sex, Utilization, Health Care
Interventions
Job announcements plus HIV prevention text messages, educational sessions, economic resources, and mentoring., Job announcements
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 30, 2026, 1:27 PM EDT
Recruiting Not applicable Interventional

Quitting Matters Human Immunodeficiency Virus Hybrid Trial

NCT06883097
View directory record Official record
Conditions
Tobacco, Tobacco Abstinence, Smoking Cessation, Smoking Cessation; Tobacco Dependence, Human Immunodeficiency Virus (HIV), Tobacco Dependence Caused by Cigarettes, Cancer Prevention
Interventions
Learn to Quit-HIV (LTQ-H) App, QuitStart
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Disparities in Rural HIV Prevention

NCT05319613
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Infections
Interventions
Virtual clinical visits with home lab kits and mailed HIV PrEP
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 30, 2026, 1:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers of Protocol Compliance and Product Adherence

NCT01804023
View directory record Official record
Conditions
HIV Prevention
Interventions
HEC placebo gel applicators
Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 3 Interventional

A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection

NCT00000750
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 9 Months
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
41
States / cities
Birmingham, Alabama • Downey, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

NCT04223791
View directory record Official record
Conditions
HIV Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
28
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Not applicable Interventional

An Avatar-based Mobile Phone Intervention to Promote Health in African American MSM

NCT04217174
View directory record Official record
Conditions
Medication Adherence, Retention in Care
Interventions
My Personal Health Guide, My Personal Food Guide
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 34 Years · Male only
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Results available

Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

NCT00201123
View directory record Official record
Conditions
Tuberculosis, AIDS-related Complex
Interventions
Aerosol Interferon-Gamma, Subcutaneous interferon-gamma, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Not applicable Interventional

Directly Observed Therapy for HIV Infected Adolescents

NCT00259389
View directory record Official record
Conditions
HIV Infections
Interventions
Directly observed therapy (DOT)
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 30, 2026, 1:27 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV

NCT07390474
View directory record Official record
Conditions
HIV
Interventions
DV201P-RNA, DV202B1-RNA
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
7
States / cities
Atlanta, Georgia • Decatur, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 4 Interventional

A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy

NCT00344760
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide, Efavirenz, lamivudine, and tenofovir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 30, 2026, 1:27 PM EDT
Not listed Phase 1 Interventional

A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)

NCT00532974
View directory record Official record
Conditions
HIV Infections
Interventions
EP1090
Biological
Lead sponsor
Epimmune
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
West Hollywood, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 24, 2007 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Not applicable Interventional

An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)

NCT00002090
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Boston, Massachusetts • Syracuse, New York • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults

NCT04871113
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3810109A, Dolutegravir+lamivudine SOC regimen
Biological
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 30, 2026, 1:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

NCT01848340
View directory record Official record
Conditions
HIV-associated Lipodystrophy Syndrome
Interventions
GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Oct 30, 2026, 1:27 PM EDT